Join to View Full Profile
44151 15th St WSte 101Lancaster, CA 93534
Phone+1 661-902-5600
Fax+1 661-951-0686
Dr. Asghari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2017 - 2020
Johns Hopkins UniversityResidency, Internal Medicine, 2014 - 2017
University of Florida College of MedicineClass of 2014
Certifications & Licensure
FL State Medical License 2017 - 2027
CA State Medical License Active through 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemiaHannah Asghari, Jeffrey E. Lancet
Leukemia & Lymphoma. 2020-02-08 - 5 citationsTumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics.Hannah Asghari, Chetasi Talati
Current Opinion in Hematology. 2020-01-09
Abstracts/Posters
- Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell TransplantationHannah Asghari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients _70 Years with Acute M...Hannah H Asghari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell TransplantationHannah H Asghari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
